UB Paderborn / Katalog / Suche / in CDI

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

CPT: pharmacometrics and systems pharmacology, 2019-06, Vol.8 (6), p.415-427

2019

Link zum Volltext

Verfügbarkeit prüfen

Covariate modeling in pharmacometrics: General points for consideration

CPT: pharmacometrics and systems pharmacology, 2024-05, Vol.13 (5), p.710-728

2024

Link zum Volltext

Verfügbarkeit prüfen

Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures

Journal of clinical pharmacology, 2016-12, Vol.56 (12), p.1591-1602

2016

Link zum Volltext

Verfügbarkeit prüfen

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years

European journal of clinical pharmacology, 2017-06, Vol.73 (6), p.727-733

2017

Link zum Volltext

Verfügbarkeit prüfen

Extrapolation of a Brivaracetam Exposure–Response Model from Adults to Children with Focal Seizures

Clinical pharmacokinetics, 2018-07, Vol.57 (7), p.843-854

2018

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

Journal of clinical pharmacology, 2021-12, Vol.61 (12), p.1579-1591

2021

Link zum Volltext

Verfügbarkeit prüfen

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Clinical pharmacology and therapeutics, 2020-03, Vol.107 (3), p.588-596

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures

Epilepsy research, 2017-11, Vol.137, p.95-100

2017

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Journal of clinical pharmacology, 2015-08, Vol.55 (8), p.866-874

2015

Link zum Volltext

Verfügbarkeit prüfen

Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study

Cancer chemotherapy and pharmacology, 2022-12, Vol.90 (6), p.511-521

2022

Link zum Volltext

Verfügbarkeit prüfen

A receptor theory‐based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc

British journal of clinical pharmacology, 2008-04, Vol.65 (s1), p.95-106

2008

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects

Journal of clinical pharmacology, 2016-01, Vol.56 (1), p.47-55

2016

Link zum Volltext

Verfügbarkeit prüfen

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin

British journal of clinical pharmacology, 2006-12, Vol.62 (6), p.699-709

2006

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors

Journal of pharmacokinetics and pharmacodynamics, 2020-02, Vol.47 (1), p.5-18

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of ribavirin in patients with hepatitis C virus

British journal of clinical pharmacology, 2006-12, Vol.62 (6), p.710-714

2006

Link zum Volltext

Verfügbarkeit prüfen

Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling

Journal of pharmacokinetics and pharmacodynamics, 2010-04, Vol.37 (2), p.157-177

2010

Link zum Volltext

Verfügbarkeit prüfen

Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Journal of pharmacokinetics and pharmacodynamics, 2016-04, Vol.43 (2), p.123-135

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Effects of the Weak CYP3A4 Inhibitors Atorvastatin and Ethinyl Estradiol/Norgestimate on Lomitapide Pharmacokinetics in Healthy Subjects

Journal of clinical lipidology, 2015-05, Vol.9 (3), p.447-448

2015

Link zum Volltext

Verfügbarkeit prüfen

A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective

The AAPS journal, 2005-10, Vol.7 (2), p.45-E460

2005

Link zum Volltext

Verfügbarkeit prüfen

Assumption testing in population pharmacokinetic models : Illustrated with an analysis of moxonidine data from congestive heart failure patients

Journal of pharmacokinetics and biopharmaceutics, 1998-04, Vol.26 (2), p.207-246

1998

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.496-496

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects: Evaluation of the Effects of the Weak CYP3A

Journal of clinical pharmacology, 2016-01, Vol.56 (1), p.47-55

2016

Link zum Volltext

Verfügbarkeit prüfen

The population pharmacokinetics of recombinant‐ and urinary‐human follicle stimulating hormone in women

British journal of clinical pharmacology, 1998-01, Vol.45 (1), p.13-20

1998

Link zum Volltext

Verfügbarkeit prüfen

Discrimination between rival dosing histories

Pharmaceutical research, 1997-08, Vol.14 (8), p.984-991

1997

Link zum Volltext

Verfügbarkeit prüfen

A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc: A Review of the Clinical Pharmacology of Maraviroc

British journal of clinical pharmacology, 2008, Vol.65, p.95-106

2008

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Covariate modeling in pharmacometrics: General points for consideration

Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years

Extrapolation of a Brivaracetam Exposure–Response Model from Adults to Children with Focal Seizures

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study

A receptor theory‐based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc

Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors

Pharmacokinetics of ribavirin in patients with hepatitis C virus

Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling

Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Evaluation of Effects of the Weak CYP3A4 Inhibitors Atorvastatin and Ethinyl Estradiol/Norgestimate on Lomitapide Pharmacokinetics in Healthy Subjects

A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective

Assumption testing in population pharmacokinetic models : Illustrated with an analysis of moxonidine data from congestive heart failure patients

Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC)

Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects: Evaluation of the Effects of the Weak CYP3A

The population pharmacokinetics of recombinant‐ and urinary‐human follicle stimulating hormone in women

Discrimination between rival dosing histories

A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc: A Review of the Clinical Pharmacology of Maraviroc

Suchergebnisse filtern